At the 20th Congress of the European Hematology Association (EHA), Paul Richardson, MD, of Dana-Farber Cancer Institute, Boston, MA, highlights new approaches under evaluation for the management of patients with multiple myeloma that may be introduced in the clinic in the upcoming years. These agents include the monoclonal antibodies, daratumumab and elotuzumab.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates